» Articles » PMID: 34439007

Pharmacokinetic Behaviour of Enrofloxacin After Single Intramuscular Dosage in American Black Vultures ()

Overview
Specialty Pharmacology
Date 2021 Aug 27
PMID 34439007
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of the study was to investigate the intramuscular pharmacokinetics of enrofloxacin in black vultures (). The pharmacokinetics of a single intramuscular dose (10 mg/kg) of enrofloxacin was studied in six vultures. Plasma concentrations of enrofloxacin and its active metabolite, ciprofloxacin, were determined by high-performance liquid chromatography (HPLCuv). Pharmacokinetic parameters were estimated using non-compartmental and compartmental analysis. After intramuscular administration, enrofloxacin showed a rapid and complete absorption, reaching a Cmax value of 3.26 ± 0.23 μg/mL at 1.75 ± 0.53 h. A long terminal half-life of 19.58 h has been observed. Using previously published MIC values to perform a PK/PD analysis, cumulative fraction responses obtained after Monte Carlo simulation for AUC/MIC > 30, 50 and 125 were 72.93%, 72.34% and 30.86% for and 89.29%, 88.89% and 58.57% for , respectively. Cumulative fraction responses obtained for Cmax/MIC index were 33.93% and 40.18% for and , respectively. The intramuscular administration of 10 mg/kg could be appropriate to treat infectious diseases caused by gram-positive bacteria with MIC value lower than 1 µg/mL; however, although enrofloxacin showed a slow elimination in black vultures, plasma concentrations were insufficient to reach the gram-negative stablished breakpoints.

Citing Articles

Antibiotic Use in Veterinary.

Andres M Antibiotics (Basel). 2022; 11(11).

PMID: 36358194 PMC: 9686639. DOI: 10.3390/antibiotics11111539.

References
1.
Ambrose P, Grasela D, Grasela T, Passarell J, Mayer H, Pierce P . Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother. 2001; 45(10):2793-7. PMC: 90733. DOI: 10.1128/AAC.45.10.2793-2797.2001. View

2.
Vanni M, Meucci V, Tognetti R, Cagnardi P, Montesissa C, Piccirillo A . Fluoroquinolone resistance and molecular characterization of gyrA and parC quinolone resistance-determining regions in Escherichia coli isolated from poultry. Poult Sci. 2014; 93(4):856-63. DOI: 10.3382/ps.2013-03627. View

3.
Gerchman I, Lysnyansky I, Perk S, Levisohn S . In vitro susceptibilities to fluoroquinolones in current and archived Mycoplasma gallisepticum and Mycoplasma synoviae isolates from meat-type turkeys. Vet Microbiol. 2008; 131(3-4):266-76. DOI: 10.1016/j.vetmic.2008.04.006. View

4.
Drusano G, Johnson D, Rosen M, Standiford H . Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother. 1993; 37(3):483-90. PMC: 187696. DOI: 10.1128/AAC.37.3.483. View

5.
Blair J . Bumblefoot: a comparison of clinical presentation and treatment of pododermatitis in rabbits, rodents, and birds. Vet Clin North Am Exot Anim Pract. 2013; 16(3):715-35. DOI: 10.1016/j.cvex.2013.05.002. View